81 related articles for article (PubMed ID: 35497201)
1. An investigation of the metabolic activity, isozyme contribution, species differences and potential drug-drug interactions of PI-103, and the identification of efflux transporters for PI-103-
Gao L; Qin Z; Zhang B; Yin Z; Zhang X; Yang J
RSC Adv; 2020 Mar; 10(16):9610-9622. PubMed ID: 35497201
[TBL] [Abstract][Full Text] [Related]
2. Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19.
Hou L; Zhao Y; Zhao S; Zhang X; Yao X; Yang J; Wang Z; Chan ECY; Liu S
Chem Biol Interact; 2024 Jan; 387():110811. PubMed ID: 37993078
[TBL] [Abstract][Full Text] [Related]
3. Hepatic biotransformation of non-psychotropic phytocannabinoids and activity screening on cytochromes P450 and UDP-glucuronosyltransferases.
Havlasek J; Vrba J; Zatloukalova M; Papouskova B; Modriansky M; Storch J; Vacek J
Toxicol Appl Pharmacol; 2023 Oct; 476():116654. PubMed ID: 37574147
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the glucuronidating pathway of pectolinarigenin, the major active constituent of the Chinese medicine Daji, in humans and its influence on biological activities.
Liu P; Li Q; Zhu G; Zhang T; Tu D; Zhang F; Finel M; He Y; Ge G
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117280. PubMed ID: 37797876
[TBL] [Abstract][Full Text] [Related]
5. Icaritin exhibits potential drug-drug interactions through the inhibition of human UDP-glucuronosyltransferase in vitro.
Rong Y; Li N; Qiao X; Yang L; Han P; Meng Z; Gan H; Wu Z; Zhu X; Sun Y; Liu S; Dou G; Gu R
Biopharm Drug Dispos; 2024 Jun; ():. PubMed ID: 38886878
[TBL] [Abstract][Full Text] [Related]
6. Multiple circulating alkaloids and saponins from intravenous Kang-Ai injection inhibit human cytochrome P450 and UDP-glucuronosyltransferase isozymes: potential drug-drug interactions.
Qin Z; Jia M; Yang J; Xing H; Yin Z; Yao Z; Zhang X; Yao X
Chin Med; 2020; 15():69. PubMed ID: 32655683
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibitory effects of selumetinib on activity of human UDP-glucuronosyltransferases and prediction of in vivo drug-drug interactions.
Yin H; Lv X; Wang Z; Xiao S; Liang J; Sun J; Jiang L; Liu Y
Toxicol In Vitro; 2024 May; 99():105863. PubMed ID: 38823552
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Contribution of Drug-Metabolizing Enzymes in Drug-Drug Interactions of Dapivirine and Miconazole.
Valicherla GR; Graebing P; Zhang J; Zheng R; Nuttall J; Silvera P; Rohan LC
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959473
[TBL] [Abstract][Full Text] [Related]
9. The Role of Uptake and Efflux Transporters in the Disposition of Glucuronide and Sulfate Conjugates.
Järvinen E; Deng F; Kiander W; Sinokki A; Kidron H; Sjöstedt N
Front Pharmacol; 2021; 12():802539. PubMed ID: 35095509
[TBL] [Abstract][Full Text] [Related]
10. Metabolism characterization and toxicity of N-hydap, a marine candidate drug for lung cancer therapy by LC-MS method.
Lu J; Liang W; Hu Y; Zhang X; Yu P; Cai M; Xie D; Zhou Q; Zhou X; Liu Y; Wang J; Guo J; Tang L
Nat Prod Bioprospect; 2024 May; 14(1):33. PubMed ID: 38771401
[TBL] [Abstract][Full Text] [Related]
11. The Expression Profiles and Deregulation of UDP-Glycosyltransferase (
Hu DG; Marri S; Mackenzie PI; Hulin JA; McKinnon RA; Meech R
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503303
[TBL] [Abstract][Full Text] [Related]
12. Avapritinib Carries the Risk of Drug Interaction via Inhibition of UDP-Glucuronosyltransferase (UGT) 1A1.
Lv X; Wang Z; Wang Z; Yin H; Xia Y; Jiang L; Liu Y
Curr Drug Metab; 2024 May; ():. PubMed ID: 38803186
[TBL] [Abstract][Full Text] [Related]
13. Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.
Yang Y; Liu X
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32290519
[TBL] [Abstract][Full Text] [Related]
14. Mutual Modulation of the Activities of Human CYP2D6 and Four UGTs during the Metabolism of Propranolol.
Yang F; Sharma SS; Bureik M; Parr MK
Curr Issues Mol Biol; 2023 Aug; 45(9):7130-7146. PubMed ID: 37754235
[TBL] [Abstract][Full Text] [Related]
15. Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability.
Maharao N; Venitz J; Gerk PM
Biopharm Drug Dispos; 2019 Jan; 40(1):18-31. PubMed ID: 30520057
[TBL] [Abstract][Full Text] [Related]
16. Construction of humanized CYP1A2 rats using CRISPR/Cas9 to promote drug metabolism and pharmacokinetic research.
Liu J; Lu J; Yao B; Zhang Y; Huang S; Chen X; Shen Y; Wang X
Drug Metab Dispos; 2023 Oct; ():. PubMed ID: 37884392
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of napabucasin on arbidol metabolism and its mechanism research.
Nie J; Xia H; Liu YN; Yu Y; Xu RA
Front Pharmacol; 2023; 14():1292354. PubMed ID: 38094891
[TBL] [Abstract][Full Text] [Related]
18. Citalopram
Rochat B; Paus E; Maitre C; Baumann P
Vet Med (Praha); 2023 Apr; 68(4):135-144. PubMed ID: 37982088
[TBL] [Abstract][Full Text] [Related]
19. Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
Joshi P; Sonawane VR; Williams IS; McCann GJP; Gatchie L; Sharma R; Satti N; Chaudhuri B; Bharate SB
Medchemcomm; 2018 Feb; 9(2):371-382. PubMed ID: 30108931
[TBL] [Abstract][Full Text] [Related]
20. Identification of naturally occurring inhibitors in Xian-Ling-Gu-Bao capsule against the glucuronidation of estrogens.
He L; Xu C; Wang Z; Duan S; Xu J; Li C; Yao X; Gonzalez FJ; Qin Z; Yao Z
Front Pharmacol; 2022; 13():935685. PubMed ID: 35991901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
